CD30 receptor (CD30)

The **CD30 receptor** is a 120 kDa transmembrane glycoprotein and a member of the tumor necrosis factor receptor superfamily (TNFRSF8). It is primarily expressed on activated T and B lymphocytes and a subset of malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Structurally, it includes extracellular, transmembrane, and intracellular domains; the extracellular portion features cysteine-rich motifs, while the intracellular tail recruits TRAF proteins (TRAF1, 2, 3, and 5) to activate canonical and non-canonical NF-κB signaling pathways, mediating a variety of biological outcomes including proliferation, apoptosis, and cytokine secretion. CD30 serves as a biomarker and therapeutic target due to its low expression in normal tissues and high expression in certain tumors. Therapeutic strategies include antibody-drug conjugates like brentuximab vedotin, bispecific antibodies, and CAR-T cell therapies, all of which harness targeted cytotoxicity or immune activation. Safety concerns focus on off-tumor toxicity, especially because of transient CD30 expression on some activated immune cells[1][3][4][6][7].

Other names

TNFRSF8Ki-1 antigenCD30 molecule

Antibody-drug conjugate cytotoxicity (Brentuximab vedotin releases cytotoxin after internalization) Immune cell activation (bispecific antibodies recruit and activate immune effector cells via binding to CD30 and other immune markers such as CD16A) Antibody-dependent cellular cytotoxicity (ADCC) CAR-T cell–mediated cytotoxicity